{"id":347886,"date":"2026-11-16T10:46:52","date_gmt":"2026-11-16T05:16:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=347886"},"modified":"2026-11-16T10:46:52","modified_gmt":"2026-11-16T05:16:52","slug":"smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Smallcap Revenue Compounders Annual and Quarterly Profit Growth Stocks to Watch for Future Multibagger Potential: Vijaya Diagnostic, CCL Products, Paras Defence and TRIL"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Vijaya Diagnostic Rs 1,410.10. CCL Products Rs 978.15. Paras Defence Rs 1,293.30. TRIL Rs 314.80. Market caps from Rs 9,469 crore to Rs 14,528 crore. Data as of 13 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Vijaya Diagnostic, CCL Products, Paras Defence and TRIL are the 4 picks in this revenue compounders annual and quarterly profit growth stocks watchlist, with market caps between Rs 9,469 crore and Rs 14,528 crore. Vijaya Diagnostic stands out for the highest return on equity at 19.26%, while CCL Products offers the lowest PE of the group at 28.25. PE ratios run from 28.25 to 97.42, so compare each one with its industry PE before investing. All figures are as of 13 November 2026.<\/p>\n<\/p><\/div>\n<p>Revenue compounders annual and quarterly profit growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Vijaya Diagnostic, CCL Products, Paras Defence and TRIL meet that test, with market caps from Rs 9,469 crore to Rs 14,528 crore and Vijaya Diagnostic offering the highest return on equity at 19.26%. Each of these companies has a four-year revenue CAGR of at least 15 per cent, FY26 net profit growth of at least 20 per cent, latest-quarter net profit growth of at least 20 per cent year on year, a return on equity of at least 10 per cent, net profit growth in FY26 and in the latest quarter, and market capitalisation below Rs 30,000 crore.<\/p>\n<p>This list covers companies compounding sales while annual and quarterly profit keep rising, ranked by market capitalisation. Every company has complete, verifiable financials, and investors screening revenue compounders annual and quarterly profit growth stocks usually begin with size and balance sheet strength, so this list follows the same logic. All figures are as of 13 November 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=revenue-compounders-annual-and-quarterly-profit-growth-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#What_Are_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Revenue Compounders Annual and Quarterly Profit Growth Stocks and Why Do They Attract Multibagger Interest?\">What Are Revenue Compounders Annual and Quarterly Profit Growth Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\" title=\"Revenue Compounders Annual and Quarterly Profit Growth Stocks at a Glance: Price, Market Cap, PE and ROE\">Revenue Compounders Annual and Quarterly Profit Growth Stocks at a Glance: Price, Market Cap, PE and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Vijaya_Diagnostic_1513_Revenue_CAGR_Since_FY22\" title=\"Vijaya Diagnostic: 15.13% Revenue CAGR Since FY22\">Vijaya Diagnostic: 15.13% Revenue CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#CCL_Products_3211_Revenue_CAGR_Since_FY22\" title=\"CCL Products: 32.11% Revenue CAGR Since FY22\">CCL Products: 32.11% Revenue CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Paras_Defence_2765_Revenue_CAGR_Since_FY22\" title=\"Paras Defence: 27.65% Revenue CAGR Since FY22\">Paras Defence: 27.65% Revenue CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#TRIL_2170_Revenue_CAGR_Since_FY22\" title=\"TRIL: 21.70% Revenue CAGR Since FY22\">TRIL: 21.70% Revenue CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Revenue Compounders Annual and Quarterly Profit Growth Stocks: Financial Comparison on Growth and Margins\">Revenue Compounders Annual and Quarterly Profit Growth Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Vijaya_Diagnostic_CCL_Products_Paras_Defence_and_TRIL\" title=\"Institutional Holding in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL\">Institutional Holding in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks\" title=\"Risks to Weigh in Revenue Compounders Annual and Quarterly Profit Growth Stocks\">Risks to Weigh in Revenue Compounders Annual and Quarterly Profit Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks\" title=\"How to Choose Between Revenue Compounders Annual and Quarterly Profit Growth Stocks\">How to Choose Between Revenue Compounders Annual and Quarterly Profit Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_to_Watch\" title=\"Frequently Asked Questions on Revenue Compounders Annual and Quarterly Profit Growth Stocks to Watch\">Frequently Asked Questions on Revenue Compounders Annual and Quarterly Profit Growth Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Which_are_the_best_revenue_compounders_annual_and_quarterly_profit_growth_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best revenue compounders annual and quarterly profit growth stocks to watch for multibagger potential?\">Which are the best revenue compounders annual and quarterly profit growth stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Is_Vijaya_Diagnostic_a_good_stock_for_long-term_investors\" title=\"Is Vijaya Diagnostic a good stock for long-term investors?\">Is Vijaya Diagnostic a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Can_CCL_Products_become_a_multibagger_from_here\" title=\"Can CCL Products become a multibagger from here?\">Can CCL Products become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Vijaya_Diagnostic_CCL_Products_Paras_Defence_and_TRIL\" title=\"What is the market cap of Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?\">What is the market cap of Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_revenue_compounders_annual_and_quarterly_profit_growth_stocks\" title=\"What are the risks of investing in revenue compounders annual and quarterly profit growth stocks?\">What are the risks of investing in revenue compounders annual and quarterly profit growth stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#Why_is_Paras_Defence_trading_at_a_PE_of_9742\" title=\"Why is Paras Defence trading at a PE of 97.42?\">Why is Paras Defence trading at a PE of 97.42?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Vijaya_Diagnostic_CCL_Products_Paras_Defence_and_TRIL\" title=\"How much do institutions hold in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?\">How much do institutions hold in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Revenue Compounders Annual and Quarterly Profit Growth Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Revenue compounders annual and quarterly profit growth stocks are shares of companies that clear several growth and quality tests at once: a four-year revenue CAGR of at least 15 per cent, FY26 net profit growth of at least 20 per cent and latest-quarter net profit growth of at least 20 per cent year on year. The 4 here cover coffee, defence optics, diagnostics and transformers.<\/p>\n<p>A multi-year growth record together with a strong latest year and a rising latest quarter shows that demand for the business is steady and not a one-off spike. Within revenue compounders annual and quarterly profit growth stocks, all 4 companies show rising profit in FY26 and in the latest quarter, which is the first check most investors make. With revenue compounders annual and quarterly profit growth stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Anyone shortlisting revenue compounders annual and quarterly profit growth stocks should compare valuation, growth and balance sheet strength together rather than relying on one number. Read each company&#8217;s latest results and exchange filings before acting on revenue compounders annual and quarterly profit growth stocks. The figures for revenue compounders annual and quarterly profit growth stocks in this article come from NSE and BSE data and company filings, and they are complete for every name shown. Within revenue compounders annual and quarterly profit growth stocks, the common thread is rising profit backed by complete financial data. Track every result season for revenue compounders annual and quarterly profit growth stocks, because earnings growth is what supports the share price over time. For revenue compounders annual and quarterly profit growth stocks, a staggered approach across quarters helps manage valuation risk.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\"><\/span><strong>Revenue Compounders Annual and Quarterly Profit Growth Stocks at a Glance: Price, Market Cap, PE and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 13 November 2026. CCL Products has the lowest PE of the group at 28.25, while Vijaya Diagnostic posts the highest return on equity at 19.26%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Price to Book<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Dividend Yield<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/vijaya\/vijaya-diagnostic-centre-ltd-share-price-today\">Vijaya Diagnostic Centre<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,410.10<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">14,528<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">71.31<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">62.49<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">19.26%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.74<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.14%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/ccl\/ccl-products-(india)-ltd-share-price-today\">CCL Products India<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">978.15<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13,044<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.25<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.70<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.34%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4.90<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.59%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/paras\/paras-defence-and-space-technologies-ltd-share-price-today\">Paras Defence and Space Technologies<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,293.30<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10,426<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">97.42<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">47.27<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.51%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">14.31<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.04%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/taril\/transformers-and-rectifiers-(india)-ltd-share-price-today\">Transformers and Rectifiers India<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">314.80<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9,469<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">30.24<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">43.77<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.42%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5.73<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.08%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Vijaya_Diagnostic_1513_Revenue_CAGR_Since_FY22\"><\/span><strong>Vijaya Diagnostic: 15.13% Revenue CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Vijaya Diagnostic Centre runs diagnostic centres offering pathology and radiology services, with a strong base in South India. It reported FY26 revenue of Rs 835 crore, up 19.34% year on year, and net profit of Rs 172.98 crore, up 20.30%. Net profit has compounded at 11.81% a year since FY22, while revenue has grown 15.13% a year. Operating margin was 43.94% in FY26.<\/p>\n<p>In the September 2026 quarter, revenue rose 25.28% to Rs 260.34 crore and net profit grew 37.41% to Rs 59.47 crore. Domestic institutions raised their holding from 25.34% in September 2025 to 32.50% in September 2026. The stock trades at a PE of 71.31 against an industry PE of 62.49, with a return on equity of 19.26% and a price to book of 13.74.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"CCL_Products_3211_Revenue_CAGR_Since_FY22\"><\/span><strong>CCL Products: 32.11% Revenue CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>CCL Products India is one of the largest private-label and instant coffee makers in the world and exports to many countries. It reported FY26 revenue of Rs 4,465.80 crore, up 43.40% year on year, and net profit of Rs 388.11 crore, up 25.06%. Net profit has compounded at 17.39% a year since FY22, while revenue has grown 32.11% a year. Operating margin was 16.63% in FY26.<\/p>\n<p>In the September 2026 quarter, revenue rose 7.78% to Rs 1,215.99 crore and net profit grew 28.98% to Rs 130.09 crore. Foreign investors raised their holding from 10.53% in September 2025 to 12.12% in September 2026. The stock trades at a PE of 28.25 against an industry PE of 20.70, with a return on equity of 17.34% and a price to book of 4.90.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Paras_Defence_2765_Revenue_CAGR_Since_FY22\"><\/span><strong>Paras Defence: 27.65% Revenue CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Paras Defence and Space Technologies makes defence optics, electromagnetic protection systems and space optics, and has a growing drone and anti-drone portfolio. It reported FY26 revenue of Rs 492.56 crore, up 32.20% year on year, and net profit of Rs 89.45 crore, up 45.47%. Net profit has compounded at 34.81% a year since FY22, while revenue has grown 27.65% a year. Operating margin was 29.65% in FY26. The debt-to-equity ratio is 0.04, which keeps interest costs low.<\/p>\n<p>In the September 2026 quarter, revenue rose 41.98% to Rs 153.34 crore and net profit grew 57.04% to Rs 30.56 crore. Domestic institutions raised their holding from 1.47% in September 2025 to 4.63% in September 2026. The stock trades at a PE of 97.42 against an industry PE of 47.27, with a return on equity of 13.51% and a price to book of 14.31.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"TRIL_2170_Revenue_CAGR_Since_FY22\"><\/span><strong>TRIL: 21.70% Revenue CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Transformers and Rectifiers India makes power and distribution transformers and reactors for utilities and industry. It reported FY26 revenue of Rs 2,569.65 crore, up 25.28% year on year, and net profit of Rs 272.17 crore, up 25.75%. Net profit has compounded at 108.94% a year since FY22, while revenue has grown 21.70% a year. Operating margin was 17.70% in FY26.<\/p>\n<p>In the September 2026 quarter, revenue rose 56.59% to Rs 742.16 crore and net profit grew 117.88% to Rs 81.38 crore. Promoters hold 64.36% and FII and DII together hold 8.18% as of September 2026. The stock trades at a PE of 30.24 against an industry PE of 43.77, below the sector average, with a return on equity of 18.42% and a price to book of 5.73.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Revenue Compounders Annual and Quarterly Profit Growth Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these revenue compounders annual and quarterly profit growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Net Profit CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Latest Quarter Profit Growth (YoY)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Vijaya Diagnostic<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">835<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">172.98<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">19.34%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.13%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.81%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">37.41%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">CCL Products<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,465.80<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">388.11<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">43.40%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32.11%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.39%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.98%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Paras Defence<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">492.56<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">89.45<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32.20%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.65%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">34.81%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">57.04%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">TRIL<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,569.65<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">272.17<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">25.28%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.70%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">108.94%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">117.88%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these revenue compounders annual and quarterly profit growth stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Vijaya_Diagnostic_CCL_Products_Paras_Defence_and_TRIL\"><\/span><strong>Institutional Holding in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these revenue compounders annual and quarterly profit growth stocks alongside the promoter. The table uses the latest reported quarter for each. Vijaya Diagnostic has the deepest institutional backing, with FII and DII together holding 43.16% as of September 2026. Domestic institutions increased their holding over the past year in Vijaya Diagnostic (from 25.34% to 32.50%) and Paras Defence (from 1.47% to 4.63%). To see how this group fits the wider market, many investors compare it with the <a href=\"https:\/\/univest.in\/indices\/nifty-smallcap-100\/nifty-smallcap-100-share-price-today\">Nifty Smallcap 100<\/a>.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Vijaya Diagnostic<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">52.46%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.66%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32.50%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4.38%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">CCL Products<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">46.16%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.12%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.41%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.31%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Paras Defence<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">53.20%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.48%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4.63%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">34.70%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">TRIL<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">64.36%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.99%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1.19%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.46%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks\"><\/span><strong>Risks to Weigh in Revenue Compounders Annual and Quarterly Profit Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with revenue compounders annual and quarterly profit growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Past growth may not repeat.<\/li>\n<li>Share prices can move sharply in either direction.<\/li>\n<li><strong>Valuation:<\/strong> Paras Defence trades at a PE of 97.42 against an industry PE of 47.27, so earnings need to keep growing to support the price.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 4 names puts the allocation in one theme, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks\"><\/span><strong>How to Choose Between Revenue Compounders Annual and Quarterly Profit Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from revenue compounders annual and quarterly profit growth stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (20.70 to 62.49) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track net profit growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Vijaya Diagnostic, CCL Products, Paras Defence and TRIL live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among revenue compounders annual and quarterly profit growth stocks, Vijaya Diagnostic stands out for the highest return on equity at 19.26%, CCL Products for the lowest PE of the group at 28.25, TRIL for the fastest profit compounding at 108.94% a year since FY22 and TRIL for the sharpest latest-quarter profit growth at 117.88%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing revenue compounders annual and quarterly profit growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Revenue_Compounders_Annual_and_Quarterly_Profit_Growth_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Revenue Compounders Annual and Quarterly Profit Growth Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_revenue_compounders_annual_and_quarterly_profit_growth_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best revenue compounders annual and quarterly profit growth stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Vijaya Diagnostic, CCL Products, Paras Defence and TRIL are the 4 names this list highlights, with market caps of Rs 14,528 crore, Rs 13,044 crore, Rs 10,426 crore and Rs 9,469 crore respectively. Vijaya Diagnostic is notable for the highest return on equity at 19.26%. CCL Products stands out for the lowest PE of the group at 28.25. TRIL offers the fastest profit growth, 108.94% a year since FY22. TRIL brings the sharpest latest-quarter profit growth at 117.88%. These are watchlist names for revenue compounders annual and quarterly profit growth stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Vijaya_Diagnostic_a_good_stock_for_long-term_investors\"><\/span><strong>Is Vijaya Diagnostic a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Vijaya Diagnostic has a return on equity of 19.26%, a PE of 71.31 against an industry PE of 62.49 and a market cap of Rs 14,528 crore. Net profit has compounded at 11.81% a year since FY22, and FY26 revenue rose 19.34% while September 2026 quarter net profit grew 37.41%. Long-term returns in revenue compounders annual and quarterly profit growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_CCL_Products_become_a_multibagger_from_here\"><\/span><strong>Can CCL Products become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A multibagger outcome in revenue compounders annual and quarterly profit growth stocks requires earnings to keep growing faster than the market for several years. CCL Products has grown revenue at 32.11% a year since FY22 and net profit at 17.39% a year, and FY26 revenue rose 43.40%. At a PE of 28.25 against an industry PE of 20.70, valuation should be checked against that growth before investing, and no outcome is guaranteed.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Vijaya_Diagnostic_CCL_Products_Paras_Defence_and_TRIL\"><\/span><strong>What is the market cap of Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 13 November 2026, Vijaya Diagnostic has a market cap of Rs 14,528 crore, CCL Products has a market cap of Rs 13,044 crore, Paras Defence has a market cap of Rs 10,426 crore and TRIL has a market cap of Rs 9,469 crore. All of them qualify as smallcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on revenue compounders annual and quarterly profit growth stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_revenue_compounders_annual_and_quarterly_profit_growth_stocks\"><\/span><strong>What are the risks of investing in revenue compounders annual and quarterly profit growth stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Paras Defence trades at a PE of 97.42 against an industry PE of 47.27, so earnings growth needs to hold up. Diversifying across the 4 names and reviewing each quarterly result helps keep risk in check.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Paras_Defence_trading_at_a_PE_of_9742\"><\/span><strong>Why is Paras Defence trading at a PE of 97.42?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Paras Defence&#8217;s PE of 97.42 compares with an industry PE of 47.27. The market is paying a premium for a return on equity of 13.51%, profit growth of 34.81% a year since FY22 and latest-quarter profit growth of 57.04%, which also means the stock is more sensitive if growth slows. Investors in revenue compounders annual and quarterly profit growth stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Vijaya_Diagnostic_CCL_Products_Paras_Defence_and_TRIL\"><\/span><strong>How much do institutions hold in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 43.16% of Vijaya Diagnostic (10.66% and 32.50%), 33.53% of CCL Products (12.12% and 21.41%), 12.11% of Paras Defence (7.48% and 4.63%) and 8.18% of TRIL (6.99% and 1.19%). Rising institutional holding is a useful signal in revenue compounders annual and quarterly profit growth stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best revenue compounders annual and quarterly profit growth stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Vijaya Diagnostic, CCL Products, Paras Defence and TRIL are the 4 names this list highlights, with market caps of Rs 14,528 crore, Rs 13,044 crore, Rs 10,426 crore and Rs 9,469 crore respectively. Vijaya Diagnostic is notable for the highest return on equity at 19.26%. CCL Products stands out for the lowest PE of the group at 28.25. TRIL offers the fastest profit growth, 108.94% a year since FY22. TRIL brings the sharpest latest-quarter profit growth at 117.88%. These are watchlist names for revenue compounders annual and quarterly profit growth stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Vijaya Diagnostic a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Vijaya Diagnostic has a return on equity of 19.26%, a PE of 71.31 against an industry PE of 62.49 and a market cap of Rs 14,528 crore. Net profit has compounded at 11.81% a year since FY22, and FY26 revenue rose 19.34% while September 2026 quarter net profit grew 37.41%. Long-term returns in revenue compounders annual and quarterly profit growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can CCL Products become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"A multibagger outcome in revenue compounders annual and quarterly profit growth stocks requires earnings to keep growing faster than the market for several years. CCL Products has grown revenue at 32.11% a year since FY22 and net profit at 17.39% a year, and FY26 revenue rose 43.40%. At a PE of 28.25 against an industry PE of 20.70, valuation should be checked against that growth before investing, and no outcome is guaranteed.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 13 November 2026, Vijaya Diagnostic has a market cap of Rs 14,528 crore, CCL Products has a market cap of Rs 13,044 crore, Paras Defence has a market cap of Rs 10,426 crore and TRIL has a market cap of Rs 9,469 crore. All of them qualify as smallcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on revenue compounders annual and quarterly profit growth stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in revenue compounders annual and quarterly profit growth stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Paras Defence trades at a PE of 97.42 against an industry PE of 47.27, so earnings growth needs to hold up. Diversifying across the 4 names and reviewing each quarterly result helps keep risk in check.\"}},{\"@type\":\"Question\",\"name\":\"Why is Paras Defence trading at a PE of 97.42?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Paras Defence's PE of 97.42 compares with an industry PE of 47.27. The market is paying a premium for a return on equity of 13.51%, profit growth of 34.81% a year since FY22 and latest-quarter profit growth of 57.04%, which also means the stock is more sensitive if growth slows. Investors in revenue compounders annual and quarterly profit growth stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Vijaya Diagnostic, CCL Products, Paras Defence and TRIL?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 43.16% of Vijaya Diagnostic (10.66% and 32.50%), 33.53% of CCL Products (12.12% and 21.41%), 12.11% of Paras Defence (7.48% and 4.63%) and 8.18% of TRIL (6.99% and 1.19%). Rising institutional holding is a useful signal in revenue compounders annual and quarterly profit growth stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4 smallcap revenue compounders annual and quarterly profit growth stocks compared on market cap, PE, ROE, growth and institutional holding: Vijaya Diagnostic, CCL Products, Paras Defence and TRIL.<\/p>\n","protected":false},"author":33,"featured_media":347885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[23953,23959],"class_list":["post-347886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-revenue-compounders-annual-and-quarterly-profit-growth-stocks","tag-smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["347885"],"rank_math_title":["Revenue Compounders Annual and Quarterly Profit Growth Stocks"],"rank_math_description":["Revenue compounders annual and quarterly profit growth stocks to watch for multibagger potential: Vijaya Diagnostic, CCL Products, Paras Defence and TRIL. Compare PE."],"rank_math_focus_keyword":["revenue compounders annual and quarterly profit growth stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/4-smallcap-revenue-compounders-annual-and-quarterly-profit-growth-stocks-to.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/347886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=347886"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/347886\/revisions"}],"predecessor-version":[{"id":347887,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/347886\/revisions\/347887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/347885"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=347886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=347886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=347886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}